Business
OncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment
OncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment\n\nOncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment\n\n\n BATON ROUGE, LA--(Marketwired - May 24, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that it has been granted US Patent # 9,333,189 B2 on May 10, 2016 from the U.S. Patent and Trademark Office (USPTO), titled \"Taxane-and taxoid-protein compositions.\" The patent protects OncBioMune's novel transferring transport technology, which overcomes shortfalls in current approved taxane therapies for an array of cancers, such as paclitaxel and docetaxel. While effective and commonly used, these therapies are limited because of inefficient delivery of the drug to the tumor cell and non-specific toxicity towards healthy cells, which can cause complications ranging from inflammation to death of the patient.The patent protects the Company's novel transferrin transport technology, an innovative approach to chemotherapy to better target tumor cells and reduce toxicity to healthy cells. Specifically, claims in the patent cover novel compositions comprising the protein transferrin, and a taxane or taxoid, which does not utilize a linking group between the taxane and protein. The claims cover drug development utilizing the technology for a broad spectrum of cancers, including, but not limited to sarcoma, lymphoma, leukemia, prostate, lung and breast.A continuance of the original US patent application #13/017,173 is being pursued to also patent a paclitaxel-albumin drug which is similar to Celegene's Abraxane. \"As we prepare to enter the two, separate Phase 2 trials of ProscaVax, our lead prostate cancer vaccine, we are busy in the lab working towards development of our transferrin and albumin transport technologies,\" said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. \"We believe that our paclitaxel-gallium-transferrin composition represents a major improvement that can substantially reduce toxicity issues and improve clinical outcomes in the taxane family of drugs that are commonly prescribed today. In addition, our albumin-paclitaxel will be ...